|
| contact. |
 |
|
Erik Kinnman
Vice President, Chief Strategic Officer and Head of Investor Relations & Public Affairs
E-mail
+46 8 697 20 00 |
 |
|
 |
|
|
| Amounts in SEK million unless otherwise stated |
2004 |
2005 |
2006 |
2007 |
2008 |
| Total revenues |
787.4 |
936.6 |
1,201.1 |
1,256.4 |
1,140.6 |
| |
|
|
|
|
|
| Research and Development expenses |
535.5 |
576.0 |
650.4 |
694.3 |
670.6 |
| |
|
|
|
|
|
| Operating profit/loss before non-recurrent expenses and revenues |
-109.6 |
-20.6 |
128.6 |
55.1 |
40.1 |
| Operating profit/loss |
41.4 |
129.9 |
54.6 |
55.1 |
-386.2 |
| Profit/loss for the period |
95.6 |
176.2 |
92.7 |
79.0 |
335.4 |
|
|
|
|
|
|
| Earnings/loss per share (SEK) |
1.83 |
3.37 |
2.00 |
1.73 |
-7.28 |
| |
|
|
|
|
|
| Cash flow from operations* |
-209.0 |
-65.5 |
-88.0 |
-25.4 |
101.8 |
| |
|
|
|
|
|
| Cash and cash equivalents & short term investments |
1,585.1 |
1,621.3 |
903.9 |
760.4 |
460.1 |
| |
|
|
|
|
|
| Equity ratio (%) |
63.5 |
62.6 |
66.5 |
74.6 |
49.8 |
| |
|
|
|
|
|
*) Excluding cash flow from acquisition of Kineret®, Kepivance® and Stemgen®
|
|
|
|
|
